NYHA FC and Finerenone Response: Clinical Trial Insights
Dr. Ostrominski discusses new data from ACC 2025 showing that finerenone improves patient outcomes in HFmrEF/HFpEF, regardless of baseline NYHA class.
Media formats available
Completing the pre-test is required to access this content.
Pre-Survey
Completing the pre-survey is required to access this content.